Nexavar and Hyperthyroid - a phase IV clinical study of FDA data

Summary:

Hyperthyroid is reported as a side effect among people who take Nexavar (sorafenib tosylate), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Urso 250, and have Hepatic neoplasm malignant.

The phase IV clinical study analyzes which people have Hyperthyroid when taking Nexavar. It is created by eHealthMe based on reports of 23,142 people who have side effects when taking Nexavar from the FDA, and is updated regularly.

What is Nexavar?

Nexavar has active ingredients of sorafenib tosylate. It is often used in hepatocellular carcinoma. eHealthMe is studying from 23,250 Nexavar users. Check the latest studies of Nexavar.

What is Hyperthyroid?

Hyperthyroid is found to be associated with 1,114 drugs and 1,420 conditions by eHealthMe. Check the latest studies of Hyperthyroid.

On Jun, 20, 2026

23,142 people reported to have side effects when taking Nexavar.
Among them, 35 people (0.15%) have Hyperthyroid.

Among these 35 people:

How long have people been on Nexavar when they have Hyperthyroid? *

What is the gender of people who have Hyperthyroid when taking Nexavar? *

female: 21.21 %
male: 78.79 %

What is the age of people who have Hyperthyroid when taking Nexavar? *

What are other drugs people take besides Nexavar? *

What are other side effects people have besides Hyperthyroid? *

Diarrhea: 15 people, 42.86%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 10 people, 28.57%
Thyroiditis (inflammation of thyroid gland): 8 people, 22.86%
Malaise (a feeling of general discomfort or uneasiness): 7 people, 20.00%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 20.00%
High Blood Pressure: 6 people, 17.14%
Stomatitis (inflammation of mucous membrane of mouth): 6 people, 17.14%
Hepatic Neoplasm Malignant (liver cancer): 6 people, 17.14%
Hypoglycemia (low blood sugar): 6 people, 17.14%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 6 people, 17.14%

What are the existing conditions these people have? *

Hepatic Neoplasm Malignant (liver cancer): 9 people, 25.71%
Renal Cell Carcinoma Stage Iv (stage iv renal cell cancer have cancer that has spread to other organs, such as the lungs, liver, bones, or brain, and may have spread to lymph nodes): 4 people, 11.43%
Jaundice - Yellow Skin (a yellowish pigmentation of the skin): 4 people, 11.43%
Renal Cell Carcinoma Stage Unspecified (kidney cancer in unknown stage): 3 people, 8.57%
Cough: 3 people, 8.57%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 2 people, 5.71%
High Blood Pressure: 2 people, 5.71%
Hepatitis B: 2 people, 5.71%
Pain: 1 person, 2.86%
Multiple Myeloma (cancer of the plasma cells): 1 person, 2.86%

* Approximation only. Some reports may have incomplete information.

Do you take Nexavar and have Hyperthyroid?

- Check whether Hyperthyroid is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nexavar:

Nexavar (23,250 reports)

Hyperthyroid treatments and more:

Hyperthyroid (26,832 reports)

Browse all side effects of Nexavar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperthyroid:

Hyperthyroid (1,114 drugs)

Browse all the conditions that are associated with Hyperthyroid:

Hyperthyroid (1,420 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sorafenib tosylate (the active ingredients of Nexavar) and Nexavar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.